Developer docs
API playgroundTry for free, no card

Search company profiles

Immunis

Full company profile

uuid00009z5

Namestring
Immunis
Legal namestring
Immunis, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Immunis is a clinical-stage biotechnology company headquartered in Irvine, California, developing multi-active stem cell-derived secretome biologics that target age- and disease-related immune decline. Its core platform produces biologics derived from the secretome of partially differentiated human pluripotent stem cells, delivering a naturally balanced combination of regenerative and immunomodulatory molecules in physiological concentrations. The company's lead investigational product, IMM01-STEM, is a cell-free multi-active biologic designed to influence multiple cell-signaling pathways simultaneously — addressing muscle loss, muscle regeneration, and metabolic dysfunction without the risks associated with administering live stem cells.

The company is advancing a portfolio of clinical programs built on its secretome platform. STEM-MYO, a Phase 1/2a trial for muscle atrophy associated with knee osteoarthritis, completed in late 2024. STEM-META, a Phase 2 placebo-controlled study in seniors with sarcopenic obesity, reported a 26% improvement in gait speed versus placebo in topline interim results announced in January 2026, with absolute improvement exceeding the clinically meaningful 0.1 m/s threshold. The company is also developing STEM-K9 for canine muscle atrophy in partnership with VetBio Partners, and in March 2026 expanded into central nervous system indications through an exclusive licensing agreement with Toray Industries for IMM02-KORA, a selective opioid kappa receptor agonist targeting L-DOPA-induced dyskinesia in Parkinson's disease.

Immunis operates a pre-revenue, capital-intensive business model typical of clinical-stage biotech, with future revenue expected from therapeutic product commercialization and licensing of pipeline assets. The company has raised approximately $35 million across a $10M Series A (August 2022) and $25M Series A-1 (January 2025), with disclosed participation from Remiges Ventures, Continuum Health Ventures, BOLD Capital Partners, LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company. Its go-to-market motion is enterprise-focused, relying on institutional clinical partnerships (CIRM Alpha Stem Cell Clinics Network, UC Irvine Medical Center), scientific advisory engagement (including XPRIZE founder Dr. Peter Diamandis), and industry-conference visibility, with future commercial distribution anticipated to follow traditional pharmaceutical channels or licensing structures upon FDA approval.

Short descriptiontext

Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived secretome biologics targeting age-related immune decline, with lead candidate IMM01-STEM in trials for muscle atrophy and sarcopenic obesity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine biologics, stem cell secretome platform, muscle atrophy therapeutics, age-related disease biotech, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Medicine Biologics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Product Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech developing novel biologics for age-related diseases. Revenue potential from FDA-approved therapeutic products for muscle atrophy, sarcopenia, metabolic conditions, and Parkinson's disease dyskinesia. Business model centers on bringing secretome-based therapies through clinical development to market approval and commercialization.

immunisbiomedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1IMM01-STEM
Description

Investigational immunomodulatory secretome product derived from partially differentiated stem cells, targeting muscle atrophy and metabolic dysfunction

immunisbiomedical.com
+4 more records
Core offering1 text field

Immunis is a clinical-stage biotechnology company that develops and advances multi-active, stem cell-derived secretome biologics through FDA-regulated clinical trials. Its lead investigational product, IMM01-STEM, delivers naturally balanced regenerative and immunomodulatory factors to treat age- and disease-related muscle atrophy, sarcopenic obesity, and metabolic dysfunction. The company also in-licensed and is developing IMM02-KORA, a selective opioid kappa receptor agonist, for dyskinesia associated with Parkinson's disease, with commercialization intended through exclusive licensing partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 26% improvement in gait speed compared to placebo controls
+4 more records
Product overview1 text field

Immunis is a clinical-stage biotechnology company developing a portfolio of multi-active stem cell-derived secretome biologics. The primary investigational product is IMM01-STEM, a complex biologic comprised of regenerative factors that impact multiple signaling pathways, currently being evaluated across multiple clinical programs: STEM-MYO (Phase 1/2a for muscle atrophy associated with knee osteoarthritis) and STEM-META (Phase 2 for sarcopenic obesity). The company has also expanded its pipeline through an exclusive licensing agreement with Toray to develop IMM02-KORA for Parkinson's disease dyskinesia. All products leverage the company's secretome technology platform to deliver all-natural, all-human immune modulators in their natural physiological concentrations.

Product and service5 records
1IMM01-STEM
CategoryInvestigational biologic (stem cell-derived secretome)
Description

A novel, multi-active, cell-free biologic derived from the secretome of partially differentiated stem cells, delivering naturally balanced regenerative and immunomodulatory molecules in physiological concentrations to treat age- and disease-related muscle atrophy, muscle regeneration impairment, and metabolic dysfunction in patients.

2IMM02-KORA (KORA)
CategoryInvestigational small molecule (in-licensed)
Description

Selective opioid kappa receptor agonist drug candidate for the treatment of dyskinesia associated with Parkinson's disease, licensed exclusively from Toray Industries for development and commercialization in the United States, Canada, the European Union, and EFTA.

3STEM-MYO Program
CategoryClinical program (Phase 1/2a)
Description

Phase 1/2a clinical trial program evaluating IMM01-STEM safety and tolerability in elderly participants with muscle atrophy associated with knee osteoarthritis, conducted at UCI Health CIRM Alpha Stem Cell Clinics.

4STEM-META Program
CategoryClinical program (Phase 2)
Description

Phase 2 placebo-controlled dose expansion study of IMM01-STEM evaluating safety and efficacy on muscle strength and physical function in seniors with obesity and muscle weakness (sarcopenic obesity).

5STEM-K9 Program
CategoryVeterinary preclinical program
Description

Preclinical program evaluating IMM01-STEM for canine muscle atrophy in partnership with VetBio Partners, pursuing parallel development in companion animals.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Toray Industries
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-05
Description

Exclusive licensing agreement with Japanese pharmaceutical company Toray Industries to develop and commercialize TRK-820 (renamed IMM02-KORA/KORA), a novel selective opioid kappa receptor agonist for treatment of dyskinesia associated with Parkinson's disease. Immunis obtained exclusive rights for US, Canada, EU, and EFTA. Toray receives upfront payment, development milestones, and sales royalties.

immunisbiomedical.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Partnership with VetBio Partners for non-terminal safety studies targeting canine muscle atrophy. Pursuing parallel STEM-K9 program in dogs following preclinical success in aged mouse models and advancing clinical testing.

3Professor Irina Conboy (UC Berkeley)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-09-28
Description

Professor of Bioengineering at UC Berkeley and Editor in Chief of Rejuvenation Research joined Immunis Scientific Advisory Board. Her research on age-related and pathological changes in tissue maintenance and repair supports company's therapeutic development approach.

immunisbiomedical.com
Strategic tierCoreTypeOthersAnnounced on2024-09-15
Description

FDA awarded Phase 1/2a clinical trial for IMM01-STEM in muscle atrophy; FDA granted clearance for Phase II sarcopenic obesity trial; IND submitted for IMM02-KORA Parkinson's dyskinesia candidate.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2024-07-25
Description

Partnership with Springbok Analytics, a life sciences muscle analytics company using MRI-based AI muscle analysis technology. Immunis uses Springbok's technology to evaluate efficacy of IMMUNA secretome therapeutic in restoring muscle growth and function in sarcopenic Phase 1/2a clinical trial population.

6CIRM Alpha Stem Cell Clinics Network
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-13
Description

Clinical trial agreement with California Institute of Regenerative Medicine Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. Network provides infrastructure and expertise for accelerated delivery of stem cell-based treatments through partnerships between patients, medical providers, and clinical trial sponsors.

immunisbiomedical.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-08-15
Description

Research collaboration with Professor Micah J. Drummond at University of Utah investigating efficacy of immunomodulatory secretome on aged skeletal muscle. Peer-reviewed research published in GeroScience demonstrating IMM01-STEM improved muscle mass and strength during disuse and recovery in aged mouse models.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage aging biotech developing therapeutics for age-related diseases, including obesity and muscle-related indications. Direct competitor in the longevity biotech space pursuing multi-indication pipelines with similar funding profiles.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics that target senescent cells to treat age-related diseases. Comparable in indication focus (sarcopenia, ophthalmology) and platform-based approach to age-related disease intervention.

3Aeovian Pharmaceuticals
TypeDirect peer
Description

Biotech developing selective mTORC1 inhibitors for age-related diseases including sarcopenia. Closely comparable indication focus and therapeutic approach to age-related muscle and metabolic decline.

4Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage biotech developing mitochondrial-targeted therapeutics for age-related and rare diseases. Comparable in therapeutic class (novel biologics for aging indications) and clinical-stage development profile.

TypeBroad incumbent
Description

Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and age-related conditions including musculoskeletal disorders. Broader incumbent in the regenerative medicine space with overlapping muscle atrophy indications.

TypeBroad incumbent
Description

Well-capitalized biotech pursuing cellular rejuvenation programming to reverse disease, injury, and the disabilities that occur with age. Broad incumbent in aging biology research with significantly greater resources than Immunis.

TypeBroad incumbent
Description

Alphabet-backed R&D company focused on understanding the biology of aging and developing interventions for age-related diseases. Established incumbent in aging therapeutics with massive capital base and similar indication focus.

TypeBroad incumbent
Description

Clinical-stage cell therapy company developing allogeneic cellular therapies derived from the postpartum placenta, including regenerative medicine products. Comparable cellular/regenerative biology approach with Dr. Diamandis as co-founder.

9Pluristem Therapeutics
TypeDirect peer
Description

Clinical-stage cell therapy company using placenta-derived cell products for inflammatory, muscle injury, and age-related indications. Closely comparable cell-based therapeutic approach targeting similar muscle and inflammatory disease indications.

TypeEmerging player
Description

Veterinary longevity therapeutics company developing drugs to extend dog healthspan. Emerging player in the canine muscle atrophy/anti-aging veterinary space, directly comparable to Immunis's STEM-K9 program.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunis

Regenerative Medicine Biologicsimmunisbiomedical.com

Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived secretome biologics targeting age-related immune decline, with lead candidate IMM01-STEM in trials for muscle atrophy and sarcopenic obesity.

What Immunis does

Immunis is a clinical-stage biotechnology company headquartered in Irvine, California, developing multi-active stem cell-derived secretome biologics that target age- and disease-related immune decline. Its core platform produces biologics derived from the secretome of partially differentiated human pluripotent stem cells, delivering a naturally balanced combination of regenerative and immunomodulatory molecules in physiological concentrations. The company's lead investigational product, IMM01-STEM, is a cell-free multi-active biologic designed to influence multiple cell-signaling pathways simultaneously — addressing muscle loss, muscle regeneration, and metabolic dysfunction without the risks associated with administering live stem cells.

The company is advancing a portfolio of clinical programs built on its secretome platform. STEM-MYO, a Phase 1/2a trial for muscle atrophy associated with knee osteoarthritis, completed in late 2024. STEM-META, a Phase 2 placebo-controlled study in seniors with sarcopenic obesity, reported a 26% improvement in gait speed versus placebo in topline interim results announced in January 2026, with absolute improvement exceeding the clinically meaningful 0.1 m/s threshold. The company is also developing STEM-K9 for canine muscle atrophy in partnership with VetBio Partners, and in March 2026 expanded into central nervous system indications through an exclusive licensing agreement with Toray Industries for IMM02-KORA, a selective opioid kappa receptor agonist targeting L-DOPA-induced dyskinesia in Parkinson's disease.

Immunis operates a pre-revenue, capital-intensive business model typical of clinical-stage biotech, with future revenue expected from therapeutic product commercialization and licensing of pipeline assets. The company has raised approximately $35 million across a $10M Series A (August 2022) and $25M Series A-1 (January 2025), with disclosed participation from Remiges Ventures, Continuum Health Ventures, BOLD Capital Partners, LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company. Its go-to-market motion is enterprise-focused, relying on institutional clinical partnerships (CIRM Alpha Stem Cell Clinics Network, UC Irvine Medical Center), scientific advisory engagement (including XPRIZE founder Dr. Peter Diamandis), and industry-conference visibility, with future commercial distribution anticipated to follow traditional pharmaceutical channels or licensing structures upon FDA approval.

Immunis firmographics

Firmographics
Name
Immunis
Legal name
Immunis, Inc.
Website
https://immunisbiomedical.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived secretome biologics targeting age-related immune decline, with lead candidate IMM01-STEM in trials for muscle atrophy and sarcopenic obesity.
Ownership category
akta.pro rank

Immunis industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Regenerative medicine biologics
  • Stem cell secretome platform
  • Muscle atrophy therapeutics
  • Age-related disease biotech
  • Clinical-stage biotechnology

Where Immunis is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Immunis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Product Development: Pre-revenue clinical-stage biotech developing novel biologics for age-related diseases. Revenue potential from FDA-approved therapeutic products for muscle atrophy, sarcopenia, metabolic conditions, and Parkinson's disease dyskinesia. Business model centers on bringing secretome-based therapies through clinical development to market approval and commercialization.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Immunis product offering

Product offering

Core offering

Immunis is a clinical-stage biotechnology company that develops and advances multi-active, stem cell-derived secretome biologics through FDA-regulated clinical trials. Its lead investigational product, IMM01-STEM, delivers naturally balanced regenerative and immunomodulatory factors to treat age- and disease-related muscle atrophy, sarcopenic obesity, and metabolic dysfunction. The company also in-licensed and is developing IMM02-KORA, a selective opioid kappa receptor agonist, for dyskinesia associated with Parkinson's disease, with commercialization intended through exclusive licensing partnerships.

Product overview

Immunis is a clinical-stage biotechnology company developing a portfolio of multi-active stem cell-derived secretome biologics. The primary investigational product is IMM01-STEM, a complex biologic comprised of regenerative factors that impact multiple signaling pathways, currently being evaluated across multiple clinical programs: STEM-MYO (Phase 1/2a for muscle atrophy associated with knee osteoarthritis) and STEM-META (Phase 2 for sarcopenic obesity). The company has also expanded its pipeline through an exclusive licensing agreement with Toray to develop IMM02-KORA for Parkinson's disease dyskinesia. All products leverage the company's secretome technology platform to deliver all-natural, all-human immune modulators in their natural physiological concentrations.

Differentiator

Problem solved

Functional benefit

Brands

  • IMM01-STEM: Investigational immunomodulatory secretome product derived from partially differentiated stem cells, targeting muscle atrophy and metabolic dysfunction
  • IMM02-KORA (KORA)
  • STEM-MYO Program
  • STEM-META Program
  • STEM-K9 Program

Products and services

  • IMM01-STEM A novel, multi-active, cell-free biologic derived from the secretome of partially differentiated stem cells, delivering naturally balanced regenerative and immunomodulatory molecules in physiological concentrations to treat age- and disease-related muscle atrophy, muscle regeneration impairment, and metabolic dysfunction in patients.
  • IMM02-KORA (KORA) Selective opioid kappa receptor agonist drug candidate for the treatment of dyskinesia associated with Parkinson's disease, licensed exclusively from Toray Industries for development and commercialization in the United States, Canada, the European Union, and EFTA.
  • STEM-MYO Program Phase 1/2a clinical trial program evaluating IMM01-STEM safety and tolerability in elderly participants with muscle atrophy associated with knee osteoarthritis, conducted at UCI Health CIRM Alpha Stem Cell Clinics.
  • STEM-META Program Phase 2 placebo-controlled dose expansion study of IMM01-STEM evaluating safety and efficacy on muscle strength and physical function in seniors with obesity and muscle weakness (sarcopenic obesity).
  • STEM-K9 Program Preclinical program evaluating IMM01-STEM for canine muscle atrophy in partnership with VetBio Partners, pursuing parallel development in companion animals.

Quantifiable outcome

  • 26% improvement in gait speed compared to placebo controls
  • +4 more outcomes

Companies that use Immunis

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Immunis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Immunis partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, supporting and strategic.

  • Toray IndustriescoreOEM/ Whitelabel/ Licensing Partner · 5 March 2026Exclusive licensing agreement with Japanese pharmaceutical company Toray Industries to develop and commercialize TRK-820 (renamed IMM02-KORA/KORA), a novel selective opioid kappa receptor agonist for treatment of dyskinesia associated with Parkinson's disease. Immunis obtained exclusive rights for US, Canada, EU, and EFTA. Toray receives upfront payment, development milestones, and sales royalties.
  • VetBio Partners, LLCsupportingStrategic or Co-development Partner · 4 November 2024Partnership with VetBio Partners for non-terminal safety studies targeting canine muscle atrophy. Pursuing parallel STEM-K9 program in dogs following preclinical success in aged mouse models and advancing clinical testing.
  • Professor Irina Conboy (UC Berkeley)supportingStrategic or Co-development Partner · 28 September 2024Professor of Bioengineering at UC Berkeley and Editor in Chief of Rejuvenation Research joined Immunis Scientific Advisory Board. Her research on age-related and pathological changes in tissue maintenance and repair supports company's therapeutic development approach.
  • FDAcoreOthers · 15 September 2024FDA awarded Phase 1/2a clinical trial for IMM01-STEM in muscle atrophy; FDA granted clearance for Phase II sarcopenic obesity trial; IND submitted for IMM02-KORA Parkinson's dyskinesia candidate.
  • Springbok AnalyticsstrategicTechnology or Integration · 25 July 2024Partnership with Springbok Analytics, a life sciences muscle analytics company using MRI-based AI muscle analysis technology. Immunis uses Springbok's technology to evaluate efficacy of IMMUNA secretome therapeutic in restoring muscle growth and function in sarcopenic Phase 1/2a clinical trial population.
  • CIRM Alpha Stem Cell Clinics NetworkcoreStrategic or Co-development Partner · 13 September 2022Clinical trial agreement with California Institute of Regenerative Medicine Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. Network provides infrastructure and expertise for accelerated delivery of stem cell-based treatments through partnerships between patients, medical providers, and clinical trial sponsors.
  • University of Utah (Dr. Micah Drummond)strategicStrategic or Co-development Partner · 15 August 2022Research collaboration with Professor Micah J. Drummond at University of Utah investigating efficacy of immunomodulatory secretome on aged skeletal muscle. Peer-reviewed research published in GeroScience demonstrating IMM01-STEM improved muscle mass and strength during disuse and recovery in aged mouse models.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Immunis competitors and assessment

Company assessment

Direct peers

  • BioAge Labs: Clinical-stage aging biotech developing therapeutics for age-related diseases, including obesity and muscle-related indications. Direct competitor in the longevity biotech space pursuing multi-indication pipelines with similar funding profiles.
  • Unity Biotechnology: Clinical-stage biotech developing therapeutics that target senescent cells to treat age-related diseases. Comparable in indication focus (sarcopenia, ophthalmology) and platform-based approach to age-related disease intervention.
  • Aeovian Pharmaceuticals: Biotech developing selective mTORC1 inhibitors for age-related diseases including sarcopenia. Closely comparable indication focus and therapeutic approach to age-related muscle and metabolic decline.
  • Stealth BioTherapeutics: Clinical-stage biotech developing mitochondrial-targeted therapeutics for age-related and rare diseases. Comparable in therapeutic class (novel biologics for aging indications) and clinical-stage development profile.
  • Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived cell products for inflammatory, muscle injury, and age-related indications. Closely comparable cell-based therapeutic approach targeting similar muscle and inflammatory disease indications.

Broad incumbents

  • Mesoblast: Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and age-related conditions including musculoskeletal disorders. Broader incumbent in the regenerative medicine space with overlapping muscle atrophy indications.
  • Altos Labs: Well-capitalized biotech pursuing cellular rejuvenation programming to reverse disease, injury, and the disabilities that occur with age. Broad incumbent in aging biology research with significantly greater resources than Immunis.
  • Calico Life Sciences: Alphabet-backed R&D company focused on understanding the biology of aging and developing interventions for age-related diseases. Established incumbent in aging therapeutics with massive capital base and similar indication focus.
  • Celularity: Clinical-stage cell therapy company developing allogeneic cellular therapies derived from the postpartum placenta, including regenerative medicine products. Comparable cellular/regenerative biology approach with Dr. Diamandis as co-founder.

Emerging players

  • Loyal for Dogs: Veterinary longevity therapeutics company developing drugs to extend dog healthspan. Emerging player in the canine muscle atrophy/anti-aging veterinary space, directly comparable to Immunis's STEM-K9 program.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Immunis social profiles

Digital presence

Immunis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunis leadership team

Management profile

Number of profiles

Profiles8 records

Immunis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunis

What does Immunis do?

Immunis is a clinical-stage biotechnology company that develops and advances multi-active, stem cell-derived secretome biologics through FDA-regulated clinical trials. Its lead investigational product, IMM01-STEM, delivers naturally balanced regenerative and immunomodulatory factors to treat age- and disease-related muscle atrophy, sarcopenic obesity, and metabolic dysfunction. The company also in-licensed and is developing IMM02-KORA, a selective opioid kappa receptor agonist, for dyskinesia associated with Parkinson's disease, with commercialization intended through exclusive licensing partnerships.

Is Immunis a public or private company?

Immunis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Immunis founded?

Immunis was founded in 2019. It employs 11 to 50 people.

Where is Immunis based?

Immunis is headquartered in Irvine, United States, in the North America region.

How does Immunis make money?

One revenue line is on record: therapeutic Product Development.

Who are Immunis's main competitors?

Direct peers on record are BioAge Labs, Unity Biotechnology, Aeovian Pharmaceuticals, Stealth BioTherapeutics and Pluristem Therapeutics. Broad incumbents are Mesoblast, Altos Labs, Calico Life Sciences and Celularity. Loyal for Dogs is listed as an emerging player.

Does Immunis have an API?

No public API is recorded for Immunis.

What industry is Immunis in?

Immunis's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyImmunis wins grand prize for novel anti-aging stem cell therapyImmunis won the Grand Prize in the National Academy of Medicine's Healthy Longevity Global Competition for its investigational therapy IMM01-STEM. The company has advanced the therapy into a randomized Phase 2 trial, with data showing improvements in muscle function, metabolism, and quality of life without severe adverse events. The therapy is being evaluated as a stand-alone treatment and as an adjunct to GLP-1 therapies.BioSpaceImmunis Chairman Dr. Hans Keirstead Nominated to Speak at SXSW 2027 on Restorative Approaches to Longevity MedicineImmunis chairman Dr. Hans Keirstead was nominated to speak at SXSW 2027 on restorative approaches to longevity medicine. The panel will discuss multi-active biologics like IMM01-STEM, which showed improved muscle function and gait speed in recent clinical data. Voting for the session is open until August 23.Business Wire BlogImmunis Chairman Dr. Hans Keirstead Nominated to Speak at SXSW 2027 on Restorative Approaches to Longevity MedicineImmunis announced that its Chairman, Dr. Hans Keirstead, has been nominated as a panelist for SXSW 2027 to discuss restorative approaches to longevity medicine. The nomination highlights the company's focus on evidence-based science and its lead therapy, IMM01-STEM, which targets muscle health and aging. The article also references a separate licensing agreement with Toray for a Parkinson’s disease treatment candidate.ParkinsonsnewstodayImmunis plans Phase 1 trial of treatment for Parkinson’s dyskinesiaImmunis has secured exclusive rights from Toray to develop and commercialize KORA for levodopa-induced dyskinesia in the U.S., Canada, the EU, and EFTA, and has submitted an application to the FDA to begin a Phase 1 clinical trial. Preclinical studies indicate that KORA effectively reduces dyskinesia symptoms in animal models without interfering with levodopa's therapeutic effects. The treatment is already approved in Japan for kidney-related itching, though its safety profile in Parkinson's patients remains to be determined.Longevity.TechnologyImmunis licenses Parkinson’s dyskinesia treatment candidate from TorayImmunis, a clinical-stage biotechnology company, has entered an exclusive licensing agreement with Toray to develop and commercialize a drug candidate (KORA/IMM02-KORA) for dyskinesia associated with Parkinson's disease. The company has submitted an Investigational New Drug application to the FDA for Phase I clinical trials, with preclinical data showing reduced L-DOPA-induced dyskinesia symptoms in rat models. The exclusive rights cover the United States, Canada, the European Union, and the European Free Trade Association.Longevity.TechnologyToray out-licenses novel Parkinson’s therapyJapanese company Toray Industries has entered an exclusive licensing agreement with Immunis, Inc. to advance TRK-820 (renamed IMM02-KORA), a drug candidate designed to treat L-dopa-induced dyskinesia in Parkinson's disease patients. Immunis gains exclusive rights to develop and commercialize the therapy in the United States, Canada, the European Union, and the European Free Trade Association, while Toray will receive upfront and milestone payments plus royalties if the drug reaches market. The therapy is described as the world's first selective opioid kappa receptor agonist, taking a mechanistic approach that differs from traditional dopamine-focused Parkinson's treatments, and Immunis submitted an Investigational New Drug application to the FDA in February 2026 to initiate a Phase I clinical trial.Business Wire BlogImmunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s DiseaseImmunis, Inc. has entered into an exclusive licensing agreement with Toray to develop and commercialize the drug candidate KORA for treating dyskinesia associated with Parkinson’s disease. Immunis holds exclusive rights in the United States, Canada, the European Union, and the European Free Trade Association, and has submitted an Investigational New Drug application to initiate Phase I clinical trials. Preclinical data indicates that KORA effectively reduces L-DOPA-induced dyskinesia symptoms in rat models.PrtimesRegarding the conclusion of a licensing agreement for Parkinson's disease dyskinesia treatment drugs and the application for the start of clinical trials to the US FDA.Toray Industries has signed an exclusive licensing agreement with Immunis, Inc. granting rights to develop and commercialize TRK-820 (renamed IMM02-KORA), a treatment for dyskinesia associated with Parkinson's disease, in the United States, Canada, the European Union, and the European Free Trade Association. Immunis submitted an Investigational New Drug application to the U.S. FDA in February to initiate Phase I clinical trials for the drug. Under the agreement, Immunis will pay Toray a one-time contract fee, development milestone payments, and sales-based royalties.Business Wire BlogImmunis Named by The Healthcare Technology Report as One of the “Top 50 Healthcare Technology Companies of 2025”Immunis Inc., a clinical-stage biotech company focused on stem cell-derived biologics for age-related diseases, has been named one of the Top 50 Healthcare Technology Companies of 2025 by The Healthcare Technology Report. The recognition highlights the company's advancement of a treatment candidate for sarcopenic obesity into a first-in-class Phase 2 clinical trial, supported by preclinical data demonstrating increased lean muscle mass and fat loss, as well as recent Series A financing. The selection committee evaluated thousands of organizations based on product quality, management team strength, technological innovation, and overall industry impact.Longevity.TechnologyImmunis reports study showing improved metabolism and liver healthImmunis Inc. announced preclinical research showing its therapeutic approach promoted fat loss, reduced liver steatosis and fibrosis, and increased lean muscle mass in aged animal models. The findings suggest potential for treating age-related metabolic and degenerative conditions, including improvements in liver and muscle health.